# Investigating Potential 5′ UTR G-Quadruplexes Within NRF2 mRNA

**Authors:** Hatice Esenkaya, Joe Bryant

PMC · DOI: 10.3390/cimb48020171 · 2026-02-02

## TL;DR

This study investigates G-quadruplex structures in the 5′ UTR of NRF2 mRNA and their role in regulating gene expression under normal conditions.

## Contribution

The study provides in vitro evidence of RNA G4s in the NRF2 5′ UTR under basal conditions using minigenes.

## Key findings

- RNA G4s in the NRF2 5′ UTR were detected using electrophoretic mobility shift assays.
- Fluorescence spectra confirmed the presence of G4 structures in the absence of stress.
- These findings suggest a structural mechanism for NRF2 regulation with implications for disease.

## Abstract

Post-transcriptional regulation of gene expression is influenced by RNA-binding proteins (RBPs) and small non-coding RNAs that bind to conserved mRNA sequences to modulate mRNA processing. These regulatory molecules affect the structural conformation of mRNAs, creating formations like G-quadruplexes (G4s), which alter translation initiation and regulatory-factor site accessibility. Recent studies have highlighted Nuclear factor erythroid 2–related factor 2 (NRF2) as a key regulator of cellular redox homeostasis and cellular response to oxidative stress. An intriguing feature of NRF2 is the structural formation of its 5′ untranslated region (UTR), which may promote or inhibit translation initiation depending on the cellular context. In this study with minigenes, we provide in vitro evidence of RNA G4s in the NRF2 mRNA’s 5′ UTR under basal (no stress) conditions. Achieved via electrophoretic mobility shift assay and fluorescence spectra in the presence of Pyridostatin. Understanding how structural motifs within NRF2 5′ UTRs influence mRNA function provides insights into a common molecular mechanism underlying diseases where NRF2 is dysregulated, like cancers, cardiovascular disease, and neurodegeneration, and highlights potential therapeutic avenues through regulation of NRF2.

## Linked entities

- **Genes:** GABPA (GA binding protein transcription factor subunit alpha) [NCBI Gene 2551]
- **Diseases:** cardiovascular disease (MONDO:0004995)

## Full-text entities

- **Genes:** MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, CCND3 (cyclin D3) [NCBI Gene 896], FMR1 (fragile X messenger ribonucleoprotein 1) [NCBI Gene 2332] {aka FMRP, FRAXA, POF, POF1}, EEF1A2 (eukaryotic translation elongation factor 1 alpha 2) [NCBI Gene 1917] {aka DEE33, EEF1AL, EF-1-alpha-2, EF1A, EIEE33, HS1}, NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893] {aka ALPS4, CMNS, N-ras, NCMS, NRAS1, NS6}, CUL3 (cullin 3) [NCBI Gene 8452] {aka CUL-3, NEDAUS, PHA2E}, SLC26A4 (solute carrier family 26 member 4) [NCBI Gene 5172] {aka DFNB4, EVA, PDS, TDH2B}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, PNKP (polynucleotide kinase 3'-phosphatase) [NCBI Gene 11284] {aka AOA4, CMT2B2, EIEE10, MCSZ, PNK}, RBX1 (ring-box 1) [NCBI Gene 9978] {aka BA554C12.1, RNF75, ROC1}, DHX15 (DEAH-box helicase 15) [NCBI Gene 1665] {aka DBP1, DDX15, PRP43, PRPF43, PrPp43p, hPrp43}, KEAP1 (kelch like ECH associated protein 1) [NCBI Gene 9817] {aka INrf2, KLHL19}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, PDLIM7 (PDZ and LIM domain 7) [NCBI Gene 9260] {aka LMP1, LMP3}
- **Diseases:** injury to (MESH:D014947), neurodegeneration (MESH:D019636), cancer (MESH:D009369), Huntington's (MESH:D006816), genetic defects (MESH:D030342), neurological disorders (MESH:D009461), metastasis (MESH:D009362), cardiovascular disease (MESH:D002318), toxicity (MESH:D064420)
- **Chemicals:** MgCl2 (MESH:D015636), NaCl (MESH:D012965), ammonium (MESH:D064751), BrdU (MESH:D001973), bromophenol blue (MESH:D001978), EDTA (MESH:D004492), boric acid (MESH:C032688), TMPyP4 (MESH:C021096), polyacrylamide (MESH:C016679), guanine (MESH:D006147), water (MESH:D014867), phenol (MESH:D019800), Li+ (MESH:D008094), oligonucleotide (MESH:D009841), DTT (MESH:D004229), HCl (MESH:D006851), ethanol (MESH:D000431), acrylamide (MESH:D020106), BRACO-19 (MESH:C454064), Glycine (MESH:D005998), H2O2 (MESH:D006861), 1H6 (-), K+ (MESH:D011188), bisacrylamide (MESH:C021221), Na+ (MESH:D012964), oxymatrine (MESH:C037573), urea (MESH:D014508), Pyridostatin (MESH:C567962), G4 (MESH:D004003), xylene cyanol (MESH:C048951), chloroform (MESH:D002725), agarose (MESH:D012685), KCl (MESH:D011189), sodium acetate (MESH:D019346), hydrogen (MESH:D006859), spermidine (MESH:D013095), ROS (MESH:D017382), heavy metals (MESH:D019216)
- **Species:** Zika virus (no rank) [taxon 64320], Human immunodeficiency virus 1 (no rank) [taxon 11676], Human immunodeficiency virus (species) [taxon 12721], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** NM23-H2 — Bos taurus (Bovine), Finite cell line (CVCL_3074)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939816/full.md

---
Source: https://tomesphere.com/paper/PMC12939816